Prostate cancer is one of the most commonly diagnosed cancers in men of developed Western countries. Globally, it is the 2nd most commonly diagnosed and 6th leading cause of cancer death in men [1]. Several risk factors such as family history, race, obesity, diet and other environmental facto...
Prostate cancer (PCa) is the leading cause of cancer-related death among men worldwide. Knowledge of the prognostic factors of PCa and the bone metastasis pattern of patients would be helpful for patients and doctors. The data of 177,255 patients with prostate cancer diagnosed between 2010 and...
This is one reality that everyone of us need to know and accept –cure may be unnecessary, or cure may not be possible.I am reminded of a friend, Steve – a British engineer who chose to settle down in Bangkok. He too had prostate cancer. He went to Singapore and was put on Intermi...
In the United Kingdom, prostate cancer is now the most common male cancer and is the second leading cause of male cancer deaths after lung cancer. Incidence statistics may be misleading, however, due to the high prevalence of occult disease. Age is the most important risk factor in ...
Reliable prognostic biomarkers to distinguish indolent from aggressive prostate cancer (PCa) are lacking. Many studies investigated microRNAs (miRs) as PCa prognostic biomarkers, often reporting inconsistent findings. We present a systematic review of th
For these reasons, and possibly because of earlier detection of low-gradeprostatecancers, prostate cancer has one of the highest survival rates of any type ofcancer. But that doesn't mean it can't be serious. It's the second leading cause of cancer death among men in the U.S., after ...
In patient GP5, CDK12 inactivation was among the first mutations, leading to a PrCa tandem duplicator phenotype and initiating the cancer around age 50, followed by rapid cancer evolution after age 57, and metastasis around age 59, 5 years prior to prostatectomy. In patient GP12, accelerated ca...
Additionally, biopsy adherence in the PLCO Cancer Screening Trial was not per protocol and was generally low,38 leading to ascertainment bias. Furthermore, while our cohort consisted of men enrolled in the PLCO Cancer Screening Trial at the age of 55 to 60 years, we believe that previous work...
Prostate cancer remains a leading cause of cancer incidence and mortality worldwide, with 1.6 million new cases and 366,000 deaths annually1. Although prostate-specific antigen (PSA) screening was associated with a 51% reduction in PrCa mortality in the United States between 1993 and 20142, the...
Although studies have found that FRG levels can reflect the prognosis of prostate cancer and the sensitivity of immunotherapy to a certain extent, the expression of these genes may be affected by the relevant metabolic levels of the individual, leading to misjudgment of the disease, so specific ...